RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nothing like some 'leaks' on the FDA ResubmissionCan I recommend everyone try to use the "quote" button so that we all can know what exactly it is you are referring to in a previous post?
In the case of TH-1902, the potential for finding a partner is much greater due to the conventional path TH-1902 has traveled (as opposed to the very unconventional path traveled by Egrifta in NASH) and the much lower cost of a partnership deal in early stage cancer versus NASH. The chances of partnership success in cancer are much higher in my opinion than in NASH. But hopefully, THTX can still do something to get NASH across the partnership fnish line as the drug would likely work.
Trogarzon wrote: Anyway, since it's only viewed has an expense and thus a negative pressure on the stock, the later the better if they don't get any partner for it. If it's good a partner will show up, otherwise it's like Nash, a dream.